Toggle navigation
HOME
NEWSFEEDS
Healthcare Industry News
Medical Devices
Biopharmaceuticals
Diagnostics
Cardiology
Interventional
Neuro
Oncology
Orthopaedic
Surgery
People
Distribution
FDA Actions
Regulatory (INTL)
Mergers & Acquisitions
Venture Capital
INDEPENDENT REPS
For MANUFACTURERS:
Find Reps NOW
Post Your Rep Opportunity
Not sure? Let us help!
For REPS and DISTRIBUTORS:
Not in FindReps? Contact us!
ISR REGISTRY:
Independent Sales Reps - USA
Not a MEMBER Yet?
Join HSMN
FORUMS
Independent Sales Reps & Distributors
The Network Bulletin Board
Getting Started in Medical Sales
Show All Forums
RESOURCES
FindReps®
Help / FAQs
INDUSTRY LINKS:
Medical Device Companies
Biopharmaceutical Companies
Professional Organizations
Government & Regulatory
Products & Services
Venture Capital
MEMBERS
Join HSMN
Forgot Username / Password
Help / FAQs
PASSWORD REQUIRED:
Company Links Listing (Manufacturers)
Products & Services Listing (Vendors)
Post in Forums
Renew Membership
Change Password
Update Contact Info
Something else? - Contact Us
ABOUT
About HSMN
Membership Info
FindReps®
Join HSMN
Help / FAQs
Submit News Release
Info for Advertisers
Contact Us
Searching News Database:
Syncra
HSMN NewsFeed - 17 Jan 2025
FDA Approves LUMAKRAS(R) (Sotorasib) in Combination with Vectibix(R) (Panitumumab) for Chemorefractory KRAS G12C-Mutated Metastatic Colorectal Cancer
Biopharmaceuticals
Oncology
FDA
HSMN NewsFeed - 16 Sep 2021
LUMAKRAS(TM) (Sotorasib) Combined With Vectibix(R) (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
Biopharmaceuticals
Oncology
HSMN NewsFeed - 8 Feb 2017
FDA Approves Amgen's Parsabiv(TM) (Etelcalcetide), First New Treatment In More Than A Decade For Secondary Hyperparathyroidism In Adult Patients On Hemodialysis
Biopharmaceuticals
Endocrinology
FDA
HSMN NewsFeed - 11 Jan 2017
Study Results Published in the Journal of the American Medical Association Show Amgen's Parsabiv(TM) (Etelcalcetide) Significantly Reduced Serum Parathyroid Hormone in Adults With Secondary Hyperparathyroidism on Hemodialysis
Biopharmaceuticals
HSMN NewsFeed - 17 Feb 2016
Impax Receives FDA Approval for Generic Version of Adderall XR(R) (mixed salts of a single-entity amphetamine product) Capsules, CII
Biopharmaceuticals
Generics
FDA
HSMN NewsFeed - 24 Mar 2011
Medtronic Announces FDA Approval of Consulta(R) and Syncra(TM) Cardiac Resynchronization Therapy-Pacemaker (CRT-P) Systems
Devices
Cardiology
FDA
HSMN NewsFeed - 10 Dec 2010
Pfizer Stops Clinical Trials of Thelin(R) and Initiates Voluntary Product Withdrawal in the Interest of Patient Safety
Biopharmaceuticals
HSMN NewsFeed - 13 Aug 2010
US WorldMeds Acquires Solstice Neurosciences
Biopharmaceuticals
Neurology
Mergers & Acquisitions
HSMN NewsFeed - 10 Mar 2008
Auriga Laboratories Announces FDA Approval of Liquadd(TM) (Dextroamphetamine Sulfate) Oral Solution for the Treatment of ADHD and Upcoming Product Launch
Biopharmaceuticals
FDA
HSMN NewsFeed - 3 May 2007
VYVANSE(TM) (lisdexamfetamine dimesylate) Receives Final DEA Schedule Classification, Clearing Way for Launch of First Prodrug Stimulant for Treatment of ADHD
Biopharmaceuticals
HSMN NewsFeed - 13 Nov 2006
Large Outcomes Study Showed Merck's ARCOXIA(R) (etoricoxib) had Similar Rates of Cardiovascular Thrombotic Events Compared to Diclofenac, the Most Prescribed Traditional NSAID Worldwide
Biopharmaceuticals
HSMN NewsFeed - 11 Oct 2006
Stonebridge Pharma and Capellon Pharmaceuticals Announce Co-Promotion Agreement to Market Symax(TM) Duotab (hyoscyamine sulfate) for Irritable Bowel Syndrome
Biopharmaceuticals
Gastroenterology
Return to NewsFeed
Additional items found!
7
Members Archive
contains 7 additional stories matching:
Syncra
(Password required)
